Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS) In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients.
Chatzantoni K, Papathanassopoulos P, Gourzoulidou E, Mouzaki A. Chatzantoni K, et al. Among authors: papathanassopoulos p. J Autoimmun. 2004 Sep;23(2):169-77. doi: 10.1016/j.jaut.2004.05.007. J Autoimmun. 2004. PMID: 15324935
Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.
Matsoukas J, Apostolopoulos V, Kalbacher H, Papini AM, Tselios T, Chatzantoni K, Biagioli T, Lolli F, Deraos S, Papathanassopoulos P, Troganis A, Mantzourani E, Mavromoustakos T, Mouzaki A. Matsoukas J, et al. Among authors: papathanassopoulos p. J Med Chem. 2005 Mar 10;48(5):1470-80. doi: 10.1021/jm040849g. J Med Chem. 2005. PMID: 15743189
Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
Deftereos SN, Koutlas E, Koutsouraki E, Kyritsis A, Papathanassopoulos P, Fakas N, Tsimourtou V, Vlaikidis N, Tavernarakis A, Voumvourakis K, Arvanitis M, Sakellariou D, DeLorenzo F. Deftereos SN, et al. Among authors: papathanassopoulos p. BMC Neurol. 2018 Nov 6;18(1):186. doi: 10.1186/s12883-018-1179-0. BMC Neurol. 2018. PMID: 30400884 Free PMC article.
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.
Action and object naming in schizophrenia.
Kambanaros M, Messinis L, Georgiou V, Papathanassopoulos P. Kambanaros M, et al. Among authors: papathanassopoulos p. J Clin Exp Neuropsychol. 2010 Dec;32(10):1083-94. doi: 10.1080/13803391003733578. Epub 2010 May 4. J Clin Exp Neuropsychol. 2010. PMID: 20446146